Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Jazz Again Sues Avadel on Xyrem Rival and ‘Misguided Agenda’ (1)

July 18, 2022, 9:17 PMUpdated: July 19, 2022, 3:20 PM

Jazz Pharmaceuticals Inc. filed a lawsuit alleging that a narcolepsy drug proposed by Avadel CNS Pharmaceuticals LLC infringes a patent related to Jazz’s Xyrem that Avadel, in a related case, has asked a Delaware federal judge to remove from Xyrem’s entry in the FDA’s registry of approved drugs.

Jazz says it received written notice on June 7 of the allegation that the patent’s claims are invalid, unenforceable, or wouldn’t be infringed by the branded rival, proposed by a unit of Avadel Pharmaceuticals PLC, according to a complaint filed July 15 in the US District Court for the District of ...